Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 3/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.53 |
| ▸ | CES1 | P23141 | 2/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.50 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SCN2B | O60939 | 3/20 | 0.44 |
| ▸ | SCN1B | Q07699 | 3/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL365236 | 0.86 | HPGD (0.65) | KAT6ACES2CES1SCN9AMYC | |
| SCHEMBL18263313 | 0.79 | RBP4 (0.48) | SCN9ASCN5A | |
| SCHEMBL1805144 | 0.78 | GAA (0.71) | KAT6ACES2CES1BCHEHPGD | |
| SCHEMBL28019087 | 0.77 | SCN9A (0.49) | SCN9ASCN5A | |
| SCHEMBL27048591 | 0.76 | CES2 (0.53) | CES2CES1SCN9ASCN2BSCN1B | |
| SCHEMBL5384443 | 0.76 | CES2 (0.63) | KAT6ACES2CES1BCHEHPGD | |
| SCHEMBL28018537 | 0.75 | SCN9A (0.53) | SCN9AHPGDSCN5A | |
| SCHEMBL26803208 | 0.75 | SCN9A (0.45) | KAT6ACES2CES1SCN9AMYC | |
| SCHEMBL28471319 | 0.74 | CES2 (0.61) | KAT6ACES2CES1BCHEHPGD | |
| SCHEMBL2646708 | 0.74 | CES2 (0.61) | KAT6ACES2CES1BCHEHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| CN-104718188-B | The benzamides of N- substitutions and its purposes in treating pain | 基因泰克公司 | 2018-08-21 | — | — | CN | disclosed |
| CN-107428683-A | N sulphonyl yl-benzamide derivatives, its preparation method and the purposes pharmaceutically of heterocyclic substituted | 上海海雁医药科技有限公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-107406380-A | N sulphonyl yl-benzamide derivatives, its preparation method and the purposes pharmaceutically of heterocyclic substituted | 上海海雁医药科技有限公司 | 2017-11-28 | — | — | CN | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-3074377-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| WO-2015078374-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| US-8592629-B2 | Sulfonamide derivatives as Nav 1.7 inhibitors | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2593428-A2 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| EP-2593432-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109701-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007868-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | SCN1A, SCN1B, SCN5A | KAT6A 1058/4885CES2 791/4885CES1 787/4885 |
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | KAT6A 3423/4885CES2 724/4885CES1 148/4885 |
| US-20130109701-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | KAT6A 2574/4885CES2 1176/4885CES1 661/4885 |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | KAT6A 1987/4885CES2 327/4885CES1 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.